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Abstract:  
Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder 
characterized by progressive muscle weakness due to the degeneration of 
motor neurons. SMA is caused by a homozygous deletion, mutation or 
rearrangement in the Survival Motor Neuron 1 (​SMN1​) gene. Survival Motor 
Neuron 2 (​SMN2​) is located tandem to ​SMN1 ​and is identical to ​SMN1 ​except 
for a single nucleotide substitution in exon 7. SMA diagnosis and carrier status 
can be determined by droplet digital PCR (ddPCR). This study sought to 
validate Bio-Rad’s ddPCR ​SMN1​and ​SMN2 ​gene determination copy number 
assay for SMA diagnosis and screening using buccal swabs specimens. Buccal 
swab specimens would be used clinically as an alternative in instances where 
SMA diagnosis is required for pediatric patients and a blood draw would cause 
distress for the child. DNA was extracted from samples provided by 20 adult 
human volunteers. Volunteers donated blood and cheek cells via two types of 
buccal swab specimens for comparison. DNA was extracted with an automated 
method and manually, depending on the specimen. ​SMN1​ and ​SMN2​ copy 
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number results were then assessed using Bio-Rad’s ddPCR ​SMN1​ and ​SMN2 
gene determination copy number assay.  The buccal swab samples did not 
provide reliable or accurate copy number results in comparison to blood 
samples. The buccal swabs investigated in this experiment are therefore not 
suitable for clinical use. Future investigations should assess whether other 
non-invasive options of DNA collection could be used clinically for SMA 
diagnosis and screening.  
 
Introduction:  
Bio-Rad’s ddPCR ​SMN1​ (Cat. # 1863500) and ​SMN2 ​(Cat. # 1863503) 
gene determination copy number assay has been previously validated in lab for 
spinal muscular atrophy (SMA) diagnosis and screening using blood samples 
collected in EDTA tubes. However, symptoms of SMA normally start to arise 
around 6 to 18 months of age, so patients being tested for SMA are usually less 
than 2 years of age. It is considerably more difficult to draw blood from an infant 
than an adult and it can often be painful for the child.  On the other hand, buccal 
swabs are a low cost and minimally invasive method of obtaining DNA. This 
would therefore be the preferable specimen type when diagnosing young 
children with SMA.  With that in mind, the purpose of this experiment was 
designed to validate Bio-Rad’s ddPCR ​SMN1​ and ​SMN2 ​gene determination 
copy number assay using buccal swab specimens as an alternative to blood. 
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The validation of this assay using buccal swabs would possibly improve patient 
care and ease the workflow of healthcare professionals.  
 
Literature Review  
I. What is SMA  
SMA Overview  
Spinal Muscular Atrophy (SMA) is an autosomal recessive disorder 
classified by the degeneration of the motor neurons within the spinal cord (1). 
SMA results in progressive muscle weakness that is usually more severe in 
proximal areas of the body. As one of the leading genetic causes of infant death, 
SMA is seen in one in 8,000-10,000 births with a carrier frequency of about 
1:40-60 in Caucasian populations (2). When diagnosed, SMA is further 
classified into more specific subtypes: 0, I, II, III and IV (1). Type 0 is the rarest 
form of SMA and is often evident prematurely. Fetuses are less active in the 
womb and born with joint deformities and hypotonia. Type 0 SMA is so severe 
that affected children often die in early infancy (1). Type I disease, also known 
as Werdnig-Hoffmann disease, is the most common type of SMA accounting for 
about half of known cases. SMA Type I is diagnosed before 6 months of age 
and children often have no control of their head movement and cannot sit 
without support. The severity of this condition often results in death at around 
two years of age (1). On the other hand, patients with Type II SMA are known to 
exhibit symptoms between 7 and 18 months of age. Symptoms are intermediate 
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in severity as children are able to sit up without assistance but cannot walk on 
their own. Respiratory insufficiency is the main cause of death, usually occurring 
after 2 years of age (1). Type III SMA, also known as Kugelberg-Welander 
disease, is diagnosed using a wide range of symptoms. Some patients achieve 
all typical motor milestones and only minor muscle weakness later in their adult 
life. Conversely, other patients will have more debilitating symptoms and require 
a wheelchair (1). The mildest form is Type IV SMA, characterized by muscle 
weakness, arises in the second or third decade of life. Patients experience only 
mild motor impairment (1) .  
 
Pathogenesis 
Significant progress has been made over the years in regards to 
understanding the mechanism behind SMA. Research accelerated in 1990 
when scientists first mapped the locus of the SMA gene, deemed ​SMN​ (survival 
motor neuron) to chromosome 5 band q13 (1). It has since been determined that 
SMA occurs when there is a homozygous deletion or mutation in​ SMN1 ​(ID: 
6606). ​SMN1​ located at the telomeric end of 5q13 and it primarily produces 
SMN protein (1).  
SMN is located in all body cells, with highest levels in the motor neurons. 
Motor neurons are found in the spinal cord and brainstem to transmit signals to 
the body’s muscle fibers.  The end result of the signal is a muscle contraction 
which is the basis of motor function (1). SMN protein plays a crucial role in 
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splicing pre-mRNA before it is translated into protein ​(3)​. SMN is associated with 
SIP1 (creating the SMN-Gemin complex) and the two interact with spliceosomal 
small nuclear ribonucleoproteins (snRNPs). snRNPs influence pre mRNA 
processing mechanisms such as splicing and require the SMN-Gemin complex 
to function properly (1). The SMN-Germin complex helps ensure that the correct 
pre-mRNA molecules are being spliced the correct way by the correct snRNP.  
In SMA, SMN deficiency leads to SMN-Germin complex deficiencies 
which then alters concentrations of snRNPs. Fluctuating snRNP concentrations 
lead to pre-mRNA processing errors in all cells, but specifically motor neurons 
(1)​. Significant pre-mRNA processing errors central to motor neurons could 
explain the physical symptoms of people with SMA. snRNP assembly and 
production is also typically very high during embryonic and postnatal 
development to account for peak transcriptional activity during myogenic and 
neuronal differentiation (4). A lack of snRNPs due to SMN deficiency during 
periods of mass cell differentiation could be behind why motor neurons 
degenerate in SMA patients (1).  
However, the answer to why a lack of SMN protein causes such a 
negative response in specifically motor neurons is still widely unknown. Multiple 
studies suggest that SMN protein functions to support cellular functions 
pertinent to motor neurons specifically (5 & 6).  Zhang et al. (2006) and Fan & 
Simard (2002) both reported that SMN protein is sequestered in 
ribonucleoprotein granules within motor neuron neurites and growth cones. The 
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sequestering of SMN protein in motor neurons suggests that this protein plays 
an important role and is needed continuously by the cells, but no clear 
conclusions have been made. SMN protein is also known to interact with hnRNP 
R and Q, RNA binding proteins that specifically target the 3’ region of B-actin 
mRNA. Therefore, an absence of SMN protein may be linked to a deficiency of 
B-actin in the motor neurons resulting in deficits in axonal outgrowth and 
guidance (1). Inhibition of axonal outgrowth and guidance could then contribute 
to the atrophy of motor neurons seen in SMA patients (1). The relationship 
between axonal growth and SMA seems plausible, as without proper axon 
formation the motor neuron cannot complete its primary function - transmit 
signals from neurons to muscles.  
It is also relevant to note that located tandem to ​SMN1​ is ​SMN2​ (ID: 
6067)), a gene almost identical to ​SMN1​. However due to a C to T point 
mutation in exon 7, ​SMN2​ is alternatively spliced to generate a shortened 
transcript  product missing either exon 7 or exon 5 ​(7)​.  This protein product is 
nonfunctional and subsequently degraded. Fortunately, scientists have 
discovered that despite the mutation, 10%-50% of ​SMN2​ product is actually 
properly spliced and can be translated into fully functional SMN protein ​(7)​. 
Therefore, the prognosis of a SMA patient is dependent on the number of copies 
of ​SMN2​ (the more copies a patient has, the more functional SMN protein 
produced) and the fraction of functional protein produced from ​SMN2​ ​(7)​.  
 
9 
 
Mackay  
 
II. SMA Treatment  
For years, there were no treatment options for patients with SMA. With 
the exception of clinical trials, there was little parents and doctors could do for 
children born with this condition. However, on December 23rd, 2016 the FDA 
approved the first drug treatment for SMA called Spinraza (nusinersen) ​(8). 
Spinraza is a modified antisense oligonucleotide (ASO) specific to the pre-mRNA 
of ​SMN2​ (9). The drug targets an intron downstream of exon 7; the exon 
necessary to form functional protein product (10). By binding at this site, 
Spinraza mediates the splicing of ​SMN2​ to ensure exon 7 is included and 
functional SMN protein is produced. An increase in SMN protein decreases the 
severity of the SMA phenotype, as 40% of the patients in the FDA’s interim 
analysis treatment group showed considerate improvements (10). Some children 
were even able to stand and sit unassisted, prompting the FDA to accelerate its 
approval for the drug and since its release the drug has improved the lives of 
countless SMA patients (10).  
Even more recently, the FDA approved a gene therapy for SMA. 
Zolgensma (onasemnogene abeparvovec-xioi) was approved May 24th, 2019 to 
treat Type I SMA in patients less than 2 years of age (11) . The gene therapy 
provides patients with a functional copy of ​SMN1 ​resulting in the production of 
functional SMN protein, reversing and preventing motor neuron loss and 
subsequent muscular atrophy. The main benefit to this medication versus 
Spinraza is that it only needs to be administered once in a patient's life via an IV 
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infusion (11). It will be interesting to see in the coming years how Spinraza and 
Zolgensma are utilized by physicians and patients; if one will be used more than 
the other.  
 
III. What is ddPCR  
The purpose of this study was to investigate whether SMA could be 
successfully diagnosed and screened using buccal swab DNA on Bio-Rad’s 
droplet digital PCR (ddPCR) assay. ddPCR is a version of digital PCR (dPCR) 
that specifically uses water-oil emulsion droplets as a way to partition DNA 
molecules (12). Each sample contained in a 96 well PCR plate is further divided 
into 10,000-20,000 droplets and during the PCR run, the contents of each 
droplet are further amplified (12). Each droplet serves essentially the same 
function as a well in a PCR plate. The PCR amplification itself follows the same 
standard procedure as most approved Taqman-based assays. Following 
amplification, each droplet within each well is analyzed to see if it positive or 
negative for the target or reference DNA template based on the presence or 
absence of specific fluorophores (12). Bio-rad’s Quantasoft software will then fit 
the proportion of positive droplets per sample on a graph using Poisson 
distribution and use Poisson statistics to calculate the concentration of the target 
and reference gene.  
The Poisson distribution is a useful statistical tool when the events in 
question are something that can be quantified using whole numbers, occurs 
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independently of each other and can be counted (13).  In the context of ddPCR, 
the Poisson distribution served the purpose of accurately predicting the number 
of independent events in a given sample when the average rate of occurrence is 
known (15). In this experiment, the independent events refer to the generation of 
positive droplets, either for ​RNaseP​, ​SMN1 or SMN2​. During droplet generation, 
the sample DNA is randomly distributed into droplets independently of each 
other (15). In other words, the occurence of one positive droplet does not 
impede the occurrence of another.  
With the conditions of Poisson’s distribution met, one can then predict the 
number of template molecules per positive droplet: 0,1,2 etc (15). The higher the 
concentration of template DNA in a given sample, the more likely it is that more 
than one copy of the DNA template exists in the positive droplets. The Poisson 
distribution accounts for this, so by using this distribution one can accurately 
determine the concentration of template DNA molecules, even in high 
concentration samples (15). The formula used for this distribution is y=-ln(1-p) 
where y = copies per droplet and p =  fraction of positive droplets (14). After 
calculating the average number of template molecules per positive droplet, it is 
therefore possible to calculate the corrected concentration of template in 
copies/20 mcL sample or copies/ mcL. Concentrations of ​SMN1​ and ​SMN2​ can 
be compared to that of the reference target to come up with a copy number (16). 
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ddPCR eliminates all the drawbacks to early versions of digital PCR, 
which rely on complex, expensive chip based partitioning assays and serial 
dilutions resulting in possible technician error. Instead, Bio-Rad’s ddPCR assay 
utilizes mass, one step partitioning (12). The act of generating multiple droplets 
per sample allows for the generation of thousands of data points per sample 
instead of one single result (12). In addition to having a high throughput, the 
mass partitioning and amplification of  ddPCR allows for absolute and simple 
quantification, extreme precision, and reduced costs. Overall, ddPCR is a very 
attractive and lucrative assay for companies and clinical laboratories (12).  
 
IV. Screening and Diagnosing of SMA  
Upon FDA approval of Spinraza, the American College of Obstetricians 
and Gynecologists (ACOG) released a statement in 2017 recommending that all 
pregnant women or women intending to become pregnant be offered carrier 
screening for SMA (2). SMA can be screened and tested for using a variety of 
assays, as long as they can determine the presence or loss of ​SMN1 ​(17). 
Researchers have previously used restriction enzyme digestion and PCR based 
assays including radioactive PCR, qPCR, competitive PCR/primer extension, 
denaturing high performance liquid chromatography, multiplex 
ligation-dependent probe amplification, quantitative capillary electrophoresis 
fragment analysis, and short amplicon melt profiling ​(7)​. Another method is to 
use an allele specific PCR assay that targets SMN products specifically (1). 
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Here ​SMN1​ and​ SMN2 ​are amplified and quantified using variation within exon 
7 to not only differentiate between the two but to quantitatively measure 
respective copy number (1). The ability to measure copy number numerically is 
an advantage of using PCR based assays with allelic specific probes. Scientists 
can then quantitate the number of ​SMN1 ​and​ SMN2​ copies a patient has per 
cell which can diagnosis SMA in addition to screening for it (1).  
Despite the numerous assays available to diagnose SMA, there is still 
research underway to find new ways to discover more accurate and streamlined 
methods of determining the presence or absence of ​SMN1 ​and ​SMN2​. Parks et. 
al (2017) set to develop a method that would allow for non-invasive prenatal 
diagnosis of SMA via relative haplotype dosage (RHDO). Cell free fetal and 
parental DNA samples underwent haplotyping and massive parallel sequencing 
targeted for a 6 Mb region around the SMN gene locus ​(18)​. The sequencing 
results were then analyzed using RHDO, which involves measuring allelic 
imbalances of SNPs to determine what combination of paternal and maternal 
alleles specific to SMN the fetus inherited ​(19)​. The study proved successful, as 
RHDO results were cross referenced with prenatal invasive testing results and 
were all accurately reported with a 100% testing specificity and sensitivity ​(18)​.  
Stabley et al. (2015) investigated whether SMN1 and SMN2 copy 
numbers can be determined using array digital PCR (dPCR). Digital PCR allows 
for quantitative detection of a target sequence without the need for a calibration 
curve ​(7)​. Calibration curves are usually necessary in PCR to determine 
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concentration by  using a set of standards (20). However with dPCR, diluted 
template or patient DNA is portioned out, in this instance scientists used an 
array chip ​(7)​. This way, some of the aliquots within the array chip will contain 
the target sequence but others will not. The abundance of target sequence can 
be extrapolated post PCR by using Poisson statistics to compare the number of 
positive partitions to the negative ones.  Positive partitions are those that contain 
the target and/ or reference sequences, negative partitions do not ​(7)​. The 
experiment proved successful, as dPCR was successful in accurately and 
precisely determining ​SMN1​ and ​SMN2​ in cell lines derived from a population of 
SMA and non-SMA patients ​(7)​.  
  
Methods: 
I. Samples  
A. Volunteers - 
20 human volunteers all from the Laboratory for Clinical Genomics and 
Advanced Technologies at Dartmouth Hitchcock Memorial Hospital donated 
blood and buccal swabs. The group of volunteers was made up of women and 
men between the ages of 21 and 60. Each acquired sample set was labeled 
with a randomly generated 4 digit number to protect the identity and genetic 
information of each volunteer.  
B. Blood Samples -  
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Each volunteer had 5 mL of blood drawn into an EDTA collection tube. 
Samples were stored at 4 °C until extracted. Blood samples were collected 
alongside Cytosoft Cytology Brush samples (denoted as Swab A).  
C. Cytosoft Cytology Brushes (Swab A) - 
Each volunteer used a Cytosoft Cytology brush to scrape the inside of 
their cheeks for 30 seconds on each cheek to collect buccal cells. The brushes 
were then placed back into the plastic wrapping. Samples were stored at room 
temperature until extracted.  
D.  Copan’s 4N6FLOQSwabs (Swab B) - 
Due to downstream technical issues with Swab A samples the decision 
was made to utilize a different but similar method of cheek cell collection. Each 
of the previous 20 volunteers used 2 of Copan’s 4N6FLOQSwabs (denoted as 
Swab B) to collect buccal cells by scraping 20 times on each cheek. The 
volunteers were then reswabbed using Swab A, to provide a point of 
comparison. Swab B samples were stored at room temperature until extraction.  
II. DNA Extraction  
A. Blood -  
DNA was extracted from blood specimens using the Qiagen EZ1 
extraction blood protocol (Cat. # 9018293) with a final elution volume of 100 ul in 
dH​2​O. Extracted samples were stored at -20 °C. Each blood sample was 
extracted within 3 days of being drawn.  
B. Swab A -  
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DNA was extracted from the brushes using the Gentra Puregene Buccal 
Cell kit (Cat. # 158845) and the Gentra Puregene Handbook Protocol for DNA 
Purification from a Buccal brush.   However, to ensure that all the available cells 
on the brush were processed,  the volumes of all the reagents required were 
doubled with the exception of alcohol which remained the same. The final 
elution volume of the extracted DNA solution was 30 mcL in DNA Hydration 
Solution. Each cheek swab was extracted within one week of being collected. 
Extracted samples were then stored in -20 degrees Celsius until testing.  
C. Swab B -  
DNA was extracted using NAObaskets and Qiagen’s automated EZ1 
buccal cell protocol (Cat.# 9015589). The DNA was then further purified using 
the genomic DNA cleanup procedure from the Qiagen QIAamp DNA Micro Kit. 
The DNA was eluted into 50 mcL of ATE buffer. Samples were stored at -20 
degrees Celsius until testing. Each cheek swab was extracted within one week 
of being collected. 
III. PCR Plate Set-up: 
After sample DNA has been extracted, Bio-Rad’s ​SMN1​ and ​SMN2​ Copy 
Number Determination kit was used to assess the copy number of ​SMN1​ and 
SMN2 ​in the 20 human volunteers. Each kit contained Bio-Rad’s proprietary 2X 
ddPCR Supermix for Probes (no dUTP), ​SMN1 & SMN2​ copy number controls 
and the corresponding 20X primer/probe for the target and reference genes. 
The target gene (either ​SMN1​ or ​SMN2​) was labeled with the fluorophore FAM 
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while the reference gene - ​RPP30 ​(ID: 10556) - was labeled with HEX.  The kits 
supplied controls for a ​SMN1​ copy number of 0, 1 and 2 and a ​SMN2​ copy 
number of 2, 3 and 4. ​Hae​III was also used in the PCR mastermixes as a 
restriction enzyme in this experiment but it was purchased separately. The 
addition of ​Hae​III ensured that the assay would work to its optimal accuracy. 
Restriction enzyme digestion and DNA fragmentation reduces sample viscosity, 
increases primer and probes access to the template molecules, and splits 
tandem repeat gene copies (14). Separating the gene copies allows the target 
molecules to be randomly partitioned into droplets yielding more accurate 
results. Restriction enzyme digestion also reduces the appearance of ‘rain’, 
droplets whose amplitude of fluorescence fall between the major positive and 
negative populations (14).  
The 96 well Bio Rad semi skirted PCR plate was set up so that each 
sample had a well for ​SMN1 ​and ​SMN2​ detection. This required two master 
mixes, one detecting ​SMN1​ and the reference gene (​RPP30​), the other 
detecting ​SMN2​ and ​RPP30​. Each master mix contains 11.5 mcL of the 2X 
ddPCR Supermix for Probes (no dUTP), 6.13 mcL of nuclease free water, 0.31 
mcL of ​Hae​III, and 1.13 mcL of the corresponding primer/probe ​per number of 
wells used plus 1​.  In other words, if the run contained 12 samples, one would 
multiply the above reagent quantities by 17, as there needs to be enough 
master mix for the 12 samples, 3 controls and NTC plus overage to account for 
pipetting error. 18 mcL of the master mix was added to each well followed by 4 
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mcL of the designated sample, copy number control or water. Samples were 
diluted down to 10 ng/mcL to ensure the amount of DNA input was consistent.  
 After the plate had been set up, it was sealed using a MicroAmp Optical 
Adhesive film seal and spun down until there were no more air bubbles visible in 
the wells. Air bubbles impede the generation of droplets, which would result in 
no copy number assessment from the droplet reader​.  
IV. Droplet Generation: 
The next step in the procedure was to partition samples using Bio-Rad’s 
QX200 Droplet Generator. This was an automated process that required loading 
the PCR plate, the empty droplet plate, cold block, pipette tip boxes, droplet 
cartridges, and oil for probes (not Evagreen) into the areas designated on the 
instrument screen (Figure 2). After the droplets were generated the droplet plate 
was sealed with a foil seal using a PX1 PCR Plate Seal heated to 180 degrees 
Celsius.  
V. Amplification:  
The droplet plate was then brought to a Bio-Rad C1000 Touch Thermal 
Cycler for amplification. The thermal cycler protocol was set for 10 min at 95°C 
to activate the DNA polymerase enzyme followed by 40 cycles of 94°C for 40 
sec for denaturation of template DNA and subsequent annealing and extension 
of primers at 53°C for one minute. The plate was then heated up to 98°C for 10 
minutes to deactivate the enzyme and held at 12°C for an hour.  
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VI. Droplet Reading​: 
The plate was loaded onto the QX200 droplet reader which used 
Quantasoft software to individually analyze every single droplet to determine the 
number PCR positive and negative droplets for both the target and reference 
genes. The droplets were taken up into the instrument and streamed through a 
multiplexed color detection system sensitive to FAM and HEX. Droplets could be 
positive for the reference gene meaning it is HEX positive, positive for the target 
sequence (​SMN1​ or ​SMN2)​ meaning it is FAM positive, positive for both, or 
negative for both (see Figure 1).  
 
Figure 1​: 2D Amplitude Presentation of Sample Results - On Bio-Rad’s QX2000 
Droplet Reader, the Quantasoft software classifies droplets into four categories: 
target gene (​SMN1 ​or ​SMN2​) positive, reference gene positive, positive for both 
the target gene and reference gene, or negative for both. The above figure color 
codes these droplets. The cluster of blue dots in the top left corner indicate the 
droplets that were positive for only ​SMN1, ​the orange droplets were those 
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positive for ​SMN1​ and ​RPP30​. The green droplets were those positive for only 
RPP30​ ​and the black droplets were those negative for both ​SMN1​ and ​RPP30​.  
 
 
Positive droplets were assigned a value of 1 and negative droplets were 
assigned a value of 0, creating a digital signal that the Quantasoft software used 
to determine the concentration of the gene. In the event that the droplet 
generator could not automatically distinguish between positive and negative 
droplets for each the fluorophores one can set the threshold manually (see 
Figure 2).  
 
Figure 2​: 1D Amplitude Presentation of Sample Results - In the featured 
sample, the Quantasoft software was unable to define the cutoff amplitude 
between positive and negative droplets for the​ RPP30​ and ​SMN1​ targets. 
Instead, the cutoff was set by the researcher by manually placing the horizontal 
pink bar. While manually determining the cutoff is a slightly subjective method of 
determining the fraction of droplets, it is a better alternative than having to 
repeat the sample.  
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The fraction of positive droplets for the reference and target genes for 
each sample was then fitted to a Poisson distribution to determine concentration 
in copies per 20 mcL well. The subsequent concentration was then further 
simplified to copies/mcL by dividing by 20. The Quantsoft software then used a 
simple ratio between the reference and target DNA concentrations to generate 
the calculated copy number for ​SMN1​ and ​SMN2​. Copy number was 
determined by calculating [target DNA concentration/reference DNA 
concentration]x2. The assumption was that all living humans have two copies of 
RPP30​, so the concentrations of ​SMN1​ and​ SMN2​ could be compared to the 
concentration of ​RPP30​ to calculate the estimated copy number.  
Subsequent to the 45-90 minute run time of the droplet generator, data 
was interpreted using Microsoft Excel software.The final copy number result was 
determined by the following chart:  
Calculated Copy Number  Reported Copy Number 
<0.05 0 
0.90 – 1.10 1 
1.80 – 2.20 2 
2.70 – 3.30 3 
3.60 – 4.40 4 
>4.5 Greater than 4 
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Table 1:​ Reportable Calculated Copy Number Results- In order for a calculated 
SMN1​ and​ SMN2​ copy number generated by the Bio-Rad’s QX200 Droplet 
Reader to be considered reportable, the result must fall within 10% of the 
closest whole integer copy number result. 
 
Results within 10% of a whole number integer were deemed reliable and 
reportable. Samples with results that fell outside the +/- 10% range were re-run. 
The reasoning behind why some samples consistently had out of range results 
will be discussed in the Discussion: Troubleshooting section.  
 
VII. Quality Control:  
All extracted samples w​ere required to have a concentration of at least 10 
ng/mcL and a 260/280 ratio of 1.6-2.0. Sample DNA concentration and purity 
were determined using a Thermo Scientific NanoDrop.  
SMN1​ and ​SMN2​ copy number results were considered valid if they met 
a variety of criteria recommended by Bio-Rad. First, results must have fallen 
within the acceptable ranges designated in the above chart (see Table 1).  If a 
calculated copy number result did not fall within a reportable region, no result 
could be reportable out to a patient or physician and was considered invalid. 
Each sample well needed to have a minimum of 10,000 total generated 
droplets.  It was also required that for each sample the concentration of the 
calculated target and reference gene be at least 100 copies /mcL.  Exceptions 
were made in instances where there were 0 copies or 1 copy of ​SMN1 ​or ​SMN2​, 
in which the calculated concentration of the target gene could be less.  
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The internal controls also needed to pass for the run to be valid. ​SMN1 
and ​SMN2​ controls needed to yield their designated copy number to ensure the 
assay was working correctly and accurately. In other words, the ​SMN1​ 2 copy 
control must yield a reportable copy number result of 2, not 0 or 1. The NTC 
could not have any positive droplets. This ensured that there was no 
contamination within the wells and that the instrument only called positive 
droplets when they were in fact there.  
 
VIII.  Statistical Analysis  
To evaluate which swab and extraction method yielded more accurate 
results on average, two double sided paired t-tests were conducted using 
Minitab 18. The test was designed to determine if there was a statistically 
significant difference between how much the Swab A and Swab B samples 
deviated (in %) from the reportable copy number result on average for both 
SMN1​ and ​SMN2​. The less the sample deviates from the true whole copy 
number result, the more accurate the result is, as a person cannot truly have 2.2 
copies of a gene, in actuality they only have 2. The average difference in 
percent deviation between the two methods was determined by calculating the 
[percent deviation of the Swab B sample result - the percent deviation of the 
Swab A sample result] for every pair of buccal swabs. 
Confidence intervals at a 95% confidence level were then conducted to 
evaluate which method on average, yielded results closer to the whole number. 
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The calculated confidence interval will indicate on average, how much the 
results of two buccal swab samples differ. If the test suggested that on average 
the Swab B yielded results closer to the true copy number value the confidence 
interval would contain only negative numbers. The software calculated the 
differences in variation by subtracting Swab A values from the Copan swab 
values. If Swab B samples had less variation, one would be subtracting a large 
number from a small number which in turn yields a negative result. The inverse 
is true if the confidence interval suggested that Swab A samples yielded results 
closer to the reportable copy number value. The confidence interval in this case 
would be positive. 
 
Results 
I. Swab A 
To determine whether Swab A with a manual extraction method would be 
a suitable method of DNA collection for clinical SMA diagnosis and screening, 
copy number results between the corresponding buccal swab and blood 
samples were compared (see Table 2). In the group of blood samples, all 20 
specimens had calculated copy number results that fell within a reportable 
range. In the group of Swab A specimens, 8 of the samples had calculated copy 
number results that fell outside the reportable regions established in the 
methods section (See Table 2 and Figure 3). Final copy number results were 
made based off traditional rounding rules.  In addition, two of the Swab A 
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samples did not have the same copy number results as the corresponding blood 
samples (see Figure 4). Swab A Sample 4167 had ​SMN1 ​copy number result of 
4 and ​SMN2 ​copy number result of 0 (see Table 2). The corresponding blood 
had a ​SMN1​ copy number of 3 (see Table 2). Swab A sample 3636 had an 
inconclusive SMN1 copy number result. The calculated ​SMN1 ​copy number was 
2.52 which does not definitively indicate any reportable copy number (see Table 
2). For the purposes of the experiment, the sample was said to have a final 
genotype of 2.5 copies of ​SMN1. ​The discrepancies between sample pair 
results and the 8 buccal swab samples that had unreportable calculated results 
both indicate that Swab A when paired with a manual extraction, is not suitable 
for clinical testing.  
 
 
Sample 
Name 
Blood 
Results 
SMN1  
Blood 
Results 
SMN2  
Average SMN1 Calculated 
Copy Number Result 
Average SMN2 Calculate 
Copy Number Result 
 
1347  2 2 1.85 1.87 
8273  2 2 1.93 1.93 
6011 2 2 1.90 1.95 
5997 2 2 1.87 1.93 
2431 2 2 2.00 2.11 
2731 2 1 1.94 0.97 
9137 2 1 2.15 1.02 
7248 2 1 2.16 1.13 
3594 2 1 2.39 1.37 
4297 2 2 2.37 2.42 
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5263 2 3 2.06 3.05 
4990 2 2 1.95 1.95 
2030 2 1 2.4 1.2 
1286 2 2 1.94 2.04 
1322 2 0 2.005 0 
4167 3 0 3.64 6.67 E-05 
6077 1 0 1.21 0.019 
3636 2 1 2.52 1.33 
7041 2 2 2.36 2.35 
1625 2 2 2.27 2.43 
Table 2.​ Copy Number Results for Cytosoft Cytology Brush Samples Group 1 
Per Run - 20 blood and buccal swab samples were run on Bio-Rad’s SMA 
ddPCR assay and the copy number results are shown. Copy number results in 
red are those that fell outside the 10% range of acceptable deviation, which 
included samples 7248, 3594, 4297, 2030, 6077, 3636, 7041, and 1625. 
Samples that had calculated copy numbers that did not correlate with the 
corresponding blood sample are highlighted in yellow.  
 
 
Figure 3 ​: Result Acceptability for Corresponding Blood Samples and Cytosoft 
Cytology Brush Samples (Swab A) - All 20 pairs of blood and Swab A samples 
were run on Bio-Rad’s ddPCR ​SMN1​ and ​SMN2​ copy number determination 
assay. All 20 blood specimens had calculated copy number results that fell 
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within a reportable range. 8 out of the 20 Swab A samples had calculated copy 
number results that fell out of reportable range.  
 
 
Figure 4​: ​SMN1​ and ​SMN2​ Copy Number Results for Corresponding Blood and 
Cytology Brush Samples (Swab A) - The overall ​SMN1​ and ​SMN2​ copy number 
results for each pair of samples were pooled together to evaluate accuracy 
between the two specimen types. For the samples that had calculated copy 
number results that fell outside of reportable range, rounding rules were used to 
determine the whole integer copy number result.  
II.  Accuracy - Copan Swab Samples (Swab B) versus Cytosoft Cytology 
Brush (Swab A) 
In response to the contradicting and unreportable calculated copy 
number results seen in the first group of collected Swab A samples, Swab A 
was not used further in the validation study. Instead, a new buccal swab (Swab 
B) extraction method was evaluated to determine if the extracted DNA 
functioned better when tested on Bio-Rad’s ddPCR ​SMN1​ and ​SMN2​ copy 
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number determination assay. This was accomplished by first comparing ​SMN1 
and ​SMN2​ copy number results between corresponding Swab A and Swab B 
samples from the same volunteer. Since the experiment was double blind, each 
volunteer was re-swabbed using Swab A in addition to Swab B and the samples 
were assigned a new random 4 digit number. ​ While there was no way to know 
which of the original blood samples correlated to which new set of buccal swab 
samples, the total ratios of total genotypes should be the same.  
In the new group of Swab A samples, 14 of the 20 samples all had 
calculated copy number results that fell outside the 10% range for reportable 
results. (See Figure 5). For these samples, the true copy number results were 
determined by rounding calculated copy number results to the nearest whole 
number.  There were also four samples with copy number results that did not 
correlate with Swab B or the blood samples (see Figure 6 and 8). There was 
one sample with 4 copies of ​SMN1​ and 0 copies of ​SMN2​, two samples with 3 
copies of​ SMN1 ​and​ SMN2​, and one sample with 2.5 copies of ​SMN1 ​and 1 
copy of ​SMN2​ (see Figure 6 and 8). These ​SMN1​ and ​SMN2​ copy number 
results were not seen in blood samples too and were therefore, incorrect.  
Within the Swab B samples, 19 of them had reportable copy number 
results (see Figure 5). There was one exception where a sample had calculated 
results that fell outside the reportable regions. However, the copy number 
results did suggest that the sample overall had 2 copies of ​SMN1​ and ​SMN2 ​via 
rounding to the nearest whole number, a genotype that was seen in the original 
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group of blood samples. So assuming this sample has 2 copies of ​SMN1​ and 
SMN2​ all the Swab B sample genotype ratios correlate with the original blood 
samples 100% (see Figure 8).  
 
 
Figure 5​: Result Acceptability for Corresponding Cytosoft Brush Samples (Swab 
A) and Copan Swab Samples (Swab B) - All 20 pairs of Swab A and Swab B 
Samples were run on Bio-Rad’s ddPCR ​SMN1​ and ​SMN2​ copy number 
determination assay. In the group of Swab A specimens, 14 samples had 
calculated copy number results that fell within a reportable reason. In the group 
of Swab B specimens, 1 sample had calculated copy number results that fell out 
of reportable range.  
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Figure 6​: S​MN1​ and ​SMN2​ Copy Number Results for Corresponding Cytology 
Brush samples (Swab A) and Copan Swab (Swab B) Samples - The overall 
SMN1​ and ​SMN2​ copy number results for each pair of samples were pooled 
together to evaluate consistency between the two specimen types. For samples 
that had calculated copy number results that fell outside of reportable range, 
rounding rules were used to determine the whole integer copy number result.  
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Figure 7​: Result Acceptability for all Blood Samples, Cytosoft Brush Samples 
(Swab A), Copan Swab Samples (Swab B) - To assess the clinical utility of 
buccal swab specimens on Bio-Rads ddPCR assay, all the calculated SMN1 
and SMN2 calculated copy number results were pooled together.  
 
Figure 8​: Resulting Copy Number Genotypes for​ SMN1​ and ​SMN2​ for Blood, 
Cytosoft Cytology Brush (Swab A) Samples, and Copan Swab Samples (Swab 
B) - The overall copy number results for each group of samples from the pool of 
20 volunteers are compared.  Only the Swab B specimens matched the original 
blood specimens in terms of how many of each genotype were present (the light 
blue and green bars).  
 
III. Sensitivity - Copan 4N6FLOQSwab (Swab B) Specimens Limited 
Limit of Detection Study 
In order to determine the lowest concentration of DNA at which the 
QX200 droplet reader could still accurately assess copy number results for 
SMN1 a​nd ​SMN2​ when using buccal swabs, a limited limit of detection study 
was performed using Swab B samples. Three different samples with three 
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different expected genotypes were diluted to 10 ng/mcL, 7.5 ng/mcL, 5 ng/mcL, 
2.5 ng/mcL, 1 ng/mcL, and 0.5 ng/mcL. After analyzing the results, the LOD was 
determined to be 7.5 ng/mcL (see Table 3).  The decision was made based off 
at what point calculated copy number results began to fall outside the 10% 
range of acceptable deviation and when the concentration of DNA target fell 
below 100 copies/ mcL when the expected copy number was 2 or greater, or 50 
copies/mcL when then expected copy number was 1. ​The samples could be 
diluted down to 7.5 ng/mcL and still yield valid results. If sample were diluted 
past that point, results began to fall outside the 10% region, as seen in red with 
samples 9111 and 5741. The concentration of the SMN1 and SMN2 target 
sequences also began to fall under the 100 copies/mcL cut off as the samples 
became more diluted, as seen in red with all three samples. An input sample 
concentration of 7.5 ng/mcL passed all QC metrics in all three samples so that 
was deemed the limit of detection.  
 
 
Concentration  SMN1 
copy 
number  
Expected 
SMN1 
copy 
number  
Concentration 
(copies of 
target/mcL)  
SMN2 
copy 
number  
Expected 
S​MN2 ​copy 
number  
Concentration 
(copies of 
target/mcL)  
Sample 3177 (10 ng/mcL) 2.02 2 
 
362 2.01 2 394 
Sample 3177 (7.5 ng/mcL) 1.99 2 305 1.98 2 317 
Sample 3177 (5.0 ng/mcL) 
 
2.05 2 192 1.91 2 191 
Sample 3177 (2.5 ng/mcL) 1.97 2 102 1.99 2 98 
Sample 3177 (1.0 ng/mcL) 1.84 2 41.8 1.86 2 45.9 
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Sample 3177 (0.5 ng/mcL) 2.02 2 24.3 1.98 2 26.5 
Sample 5741 (10 ng/mcL) 
 
1.86 2 385 2.83 3 573 
Sample 5741 (7.5 ng/mcL) 1.84 2 288 2.88 3 461 
Sample 5741 (5.0 ng/mcL) 1.84 2 182 2.79 3 288 
Sample 5741 (2.5 ng/mcL) 1.93 2 55 2.83 3 144 
Sample 5741 (1.0 ng/mcL) 1.78 2 52.7 3.08 3 52.2 
Sample 5741 (0.5 ng/mcL) 1.86 2 48.1 2.68 3 83 
Sample 9111 (10 ng/mcL) 0.946 1 185 0 0 0 
Sample 9111 (7.5 ng/mcL) 0.97 1 
 
143 0 0 0 
Sample 9111 (5.0 ng/mcL) 0.87 1 89 0 0 0 
Sample 9111 (2.5 ng/mcL) 0.89 1 56.1 0.0022 0 0.15 
Sample 9111 (1.0 ng/mcL) 1.02 1 24.1 0 0 0 
Sample 9111 (0.5 ng/mcL) 0.94 1 16.5 0 0 0 
Table 3​. Limit of Detection Study Results for ​Copan 4N6FLOQSwabs - Three of 
the Copan swabs were selected (Sample 5741, 9111, and 3177) were diluted 
down the 10 ng/mcL, 7.5 ng/mcL, 5 ng/mcL, 2.5 ng/mcL, 1 ng/mcL, and 0.5 
ng/mcL to determine at what minimum concentration of DNA could the assay 
yield reliable copy number results that also passed all the quality control metrics.  
 
IV. Precision - ​Copan 4N6FLOQSwab (Swab B) Specimens  
To determine how reproducible results from Bio-Rad’s ddPCR SMN1 and 
SMN2  assay kits were when using buccal swabs as specimens, a precision 
study was conducted using Swab B samples. Three samples were run in 
triplicate in one run to evaluate within run precision. All three samples fell within 
the 10% acceptable range of deviation for their expected copy number results, 
suggesting the assay yields precise results within a single run (see Table 4). 
Three other samples were then run once in three different PCR plates to 
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evaluate between run precision. All three samples had results indicative of the 
expected copy numbers, suggesting that the assay yields precise results run to 
run (see Table 5). 
 SMN1 
Result 
SMN2 
Result  
SMN1 
Result 
SMN2 
Result  
SMN1 
Result 
SMN2 
Result  
Expecte
d ​SMN1 
Expecte
d ​SMN2 
 
Sample 
3489 
 
1.83 0 1.9 0 1.95 0 2 0 
Sample 
9378 
 
1.91 1.95 1.88 1.85 1.92 1.84 2 2 
Sample 
3177 
1.98 1.91 2 1.95 1.96 2.04 2 2 
Table 4.​ Within Run Precision Study Results for the ​Copan 4N6FLOQSwab 
samples - Three of the Copan swab samples were run in triplicate on one PCR 
plate to determine reproducibility of result within one run of Bio-Rad’s ddPCR 
SMN1 and SMN2 Determination assay.  
 
Sample 
Number  
Run Date  SMN1 R​esult SMN2 ​Result  Expected 
SMN1 
Expected 
SMN2 
 
 Sample 4922 4.22.19 2.87 0.0006 3 0 
 Sample 4922 5.15.19 2.9 0.0011 3 0 
 Sample 4922 5.17.19 2.97 0 3 0 
Sample 7177 5.2.19 1.85 0.96 2 1 
Sample 7177 5.15.19 1.97 0.98 2 1 
Sample 7177 5.17.19 1.9 0.926 2 1 
 Sample 9876 4.22.19 1.96 0.91 2 1 
 Sample 9876 5.9.19 1.87 0.97 2 1 
 Sample 9876 5.15.19 1.93 0.98 2 1 
Table 5​. Run to Run Results for the ​Copan 4N6FLOQSwab samples​ - Three 
different samples were run three times on three different PCR plates to 
determine is copy number results from Bio-Rads ddPCR SMN1 and​ SMN2 
Determination assays were reproducible run to run.  
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V. Quality Control Metrics  
 
There where some instances were not all the QC metrics (i.e droplet 
count and target concentration in copies/mcL) were met. In the second 
collection of the Swab A  samples, some had target concentrations levels of less 
than 100 copies/ mcL. Specifically sample 9876 had a ​SMN1​ target 
concentration of 42.2 copies/mcL and a ​RPP30​ concentration of 43.2 
copies/mcL. The sample also had a​ SMN2 ​target concentration of 22.3 
copies/mcL and ​RPP30 ​concentration of 44.4 copies/mcL. Sample 2985 also 
had a ​SMN2 ​concentration of 75.4 copies/mcL. Finally sample 7177 had a 
SMN1​ and ​SMN2​ target concentration of 93 copies/mcL and 47 copies/mcL. 
The corresponding ​RPP30 ​target concentrations were also both of out of range, 
81.4 and 83 copies/mcL. However, the copy numbers from these samples were 
used and the samples were not re-run. This was decided based on the fact that 
the Cytosoft Cytology Brush specimens were already deemed unsuitable for 
clinical use. In all other instances the samples met the target concentration 
cut-off. 
There were also instances early on in the experiment where sample wells 
in the PCR plate did not meet the minimum droplet number count. However, it 
was later determined to be due to a software issue within the ​QX200 Droplet 
Generator and not an issue with the specimens. There were also instances 
where the controls did not meet the minimum droplet count. This was 
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determined to be due to control material that had approached its expiration date. 
New controls were obtained to address this issue. 
 
VI. Statistical Analysis  
The paired t-test based off the​ SMN1​ calculated copy number data had a 
resulting p value of 0.001. Similarly, the paired t-test based off the ​SMN2 ​copy 
number data had a resulting p value of 0.019. Both 0.001 and 0.019 are less 
than alpha of 0.05. There seemed to be enough evidence to support the claim 
that there was a statistically significant difference between the average percent 
deviation of copy number results between the Swab A and Swab B samples 
when assessing copy number using Bio-Rad’s ddPCR ​SMN1​ and ​SMN2 
determination kit. 
In both 95% confidence intervals conducted, all values within the two 
intervals were negative.For ​SMN1​, the calculated interval was (-14.67, -4.48). 
For ​SMN2​, the calculated interval was (-14.30,  -1.46). That means if 100 
different and independent corresponding Swab A and Swab B sample pairs 
were run, in 95 of them the resulting average difference in percent copy number 
deviation would be between -14.67 and -4.48 for ​SMN1 ​results and -14.30 and 
-1.46 for ​SMN2.   
 The negative confidence intervals suggest with 95% confidence, that the 
Swab B specimens with the automated extraction yield results closer to the 
reported copy number result. A human cannot have a partial copy of a gene, so 
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true copy number results are whole number i.e 1, 2 or 3. Therefore the closer 
the calculated copy number results are to a whole number, the more accurate 
the results are. Since it was statistically proven that the Copan swabs on 
average produce results closer to the whole number value, they are the 
preferable buccal swab specimen. 
 ​Discussion  
I. Buccal Swab Assessment  
It was apparent based off early data results that Swab A was not a 
suitable specimen for SMA diagnosis and screening when using Bio-Rad’s 
ddPCR ​SMN1​ and ​SMN2​ copy number determination assay.  There were 
multiple Swab A samples that consistently had calculated copy number results 
that fell out of reportable range and contradicted blood sample results (see 
Figure 7 and 8).  
Conversely, the copy number results from the Swab B samples did 
correlate with the blood sample results in terms of the total ​SMN1​ and ​SMN2 
copy number combinations present (see Figure 8). The correlating results that 
the Swab B along with the automated extraction might be a more suitable for 
clinical use than Swab A. The results of the statistical tests also suggest that the 
Swab B might be acceptable for clinical testing. The two double sided paired t 
tests and corresponding 95% confidence intervals supported the claim that the 
Swab B samples yielded on average results that deviated less from the 
reportable copy number results in comparison to Swab A samples.  
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The precision studies further supported the hypothesis that Swab B along 
with the automated extraction could be used as a reliable source of DNA to 
screen and diagnose SMA on Bio-Rad’s ddPCR ​SMN1​ and ​SMN2 ​gene 
determination assay. The assay correctly detected ​SMN1​ and ​SMN2​ copy 
number results for all three samples tested in triplicate within one run and in all 
three samples tested three times in separate runs. The reproducibility of the 
copy number results indicate that the assay still yields precise results when 
using the Swab B samples rather than blood samples. 
While the data and paired t-test results may suggest that Swab B 
samples yield more accurate copy number results on Bio-Rad’s ddPCR ​SMN1 
and ​SMN2​ gene determination assay when compared to the Swab A samples, 
they still might not be reliable enough for routine clinical use. In the blood 
validation, the LOD was set at 5.0 ng/mcL of DNA, however when using the 
Swab B samples, the LOD was determined to be 7.5 ng/mcL. The assay is 
therefore not as sensitive when using the buccal swabs instead of blood 
samples.  
It is also important to note that one of the Swab B samples also had copy 
number results that consistently fell out of the 10% reportable range, which 
brings into question how dependable the calculated copy number results are for 
Swab B samples. If buccal swabs were to be used clinically to diagnose and 
screen for SMA using Bio-Rads ddPCR ​SMN1 ​and ​SMN2​ gene determination 
assay, the samples needs to be at least as accurate as the previously validated 
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blood samples. SMA diagnosis is incredibly time sensitive, as motor neuron 
degeneration is permanent and the body does not replenish these cells.  An 
invalid calculated copy number result from a buccal swab specimen that results 
in a significant delay in diagnosis and treatment is unacceptable.  Since 
extracted DNA from Swab A nor Swab B proved to be as accurate and reliable 
as blood samples when tested on Bio-Rad’s ​SMN1​ and ​SMN2​ copy number 
determination assay, these buccal swab specimens are not suitable for the 
clinical diagnosis or screening of SMA.  
 
 II.   ​  ​Troubleshooting 
In an attempt to understand why the first group of collected Swab A 
samples had  calculated copy numbers that consistently fell outside the QC 
ranges of reportable copy numbers, the DNA concentration of 10 buccal 
samples and 8 blood samples were reassessed. If the concentrations used to 
make dilutions was incorrect, the amount of input DNA would have varied 
sample to sample and could explain the erroneous calculated copy number 
results. Within the group of samples reassessed, the buccal swabs had an 
average concentration decrease of 33% while the blood samples had an 
average concentration decrease of 3%. New sample dilutions were made using 
the updated DNA concentrations and samples were then re-run on the ddPCR 
assay with little difference. However, Swab A Samples that previously had 
calculated copy number results that fell out of reportable range continued to 
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have out of range results despite the new dilutions​. ​The sharp decrease in 
sample DNA concentration could have been due to an issue with ethanol 
concentration. In the manual extraction protocol, all reagent volumes were 
doubled except for ethanol, so there could have been downstream effects due to 
insufficient DNA elution.  
 In order to understand why a portion of samples from both buccal swab 
types had unreportable calculated copy numbers, Flashgels were run to 
investigate if samples had substantial DNA degradation (see Figures 11 and 
12).  While the blood samples had visibly intact DNA, all the buccal swab 
samples showed a smear within the lane, indicative of DNA degradation and 
instabilty. All the buccal swab samples exhibited degradation, regardless of 
whether they had reportable copy number results (see Figure 10). DNA 
degradation could not have been the sole cause for copy number results falling 
outside the reportable region, unless the degradation was non-uniform. If 
sample DNA underwent degradation that targeted ​RPP30​ or ​SMN1 & SMN2 
differently, it could cause the subsequent calculated copy number result to fall 
outside the reportable region, according to a Bio-Rad representative.  
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Figure 9​: Gel Electrophoresis of Blood, 
Cytosoft Cytology Brush (Swab A) and 
Copan Swab samples (Swab B) -  Lanes 1 
and 2 contained blood samples, Lanes 3 
and 4 contained Swab A samples 5741 and 
4922, Lanes 5 and 6 contains Swab B 
sample 5741 and 4922. Lane 7 contained 
the Flashgel marker 50-1500 bp ladder. The 
blood samples had no degradation evident 
from the two bright single bands high up on 
the gel in Lanes 1 and 2. There was 
degradation in all the buccal swab 
specimens, evident in the bright smear of 
DNA in lanes 3, 4, 5 and 6. 
 
Figure 10​:  Gel Electrophoresis of Cytosoft 
Cytology Brush (Swab A) and Copan Swab 
(Swab B)samples - 6 corresponding Swab A 
and B were run on a gel. Lane 1 contains 
Swab A sample 1723. Lane 2 contains Swab 
B sample 1723, circled in blue. Lane 3 
contains Swab A sample 1277, Lane 4 
contains Swab B sample 1277, Lane 5 
contains Swab A sample 2000, Lane 6 
contains Swab B 2000, Lane 7 contains 
Swab A sample 3177, Lane 8 contains Swab 
B sample 3177, Lane 9 contains Swab A 
sample 2238, Lane 10 contains Swab B 
2238, Lane 11 contains Swab A sample 4259 
and Lane 12 contains Swab B 4259.  Lane 12 
contains the Flashgel marker 50-1500 bp. All 
12 buccal swab samples had smearing of 
DNA down the gel, evidence of evidence on 
DNA degradation. This includes Swab B 
sample 1723, the only Swab B sample with 
out of range calculated copy number results. 
All buccal swab samples had a bright band at 
the top of the gel, indicating high molecular 
weight DNA, but also a bright band at the 
bottom. The bright band at the bottom of the 
gel could be the end result of DNA 
degradation.  
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To confirm that the out of range calculated copy number results were not 
the result of sample contamination, 19 out of the 20 Swab A and Swab B 
sample pairs were run on the Applied Biosystems 3500 Genetic Analyzer (Cat. # 
4406017). One sample did not have enough DNA left and so it could not be run. 
Using CGAT’s protocol for identity testing, 17 regions of short tandem repeats 
(STRs) were analyzed via capillary electrophoresis to ensure each sample pair 
had the same polymorphisms. Within all the samples run, 13 pairs had STR 
results that correlated between Swab A and B.  One sample set had results that 
could not be analyzed due to an insufficient capillary injection. Five of the 
sample sets had a STR loci missing at least one allele peak in the Swab A 
sample (see Figure 11 for an example). Further analysis of the allele peaks 
indicated that the discrepancies were due to allele dropout (ADO) rather than 
sample contamination. ADO is when a polymorphism allele is not picked up by 
sequencing because of insufficient amplification and so the allele is below the 
limit of detection (21).  When comparing the allele peaks between the Swab A 
and B samples, the peaks for the Swab B samples are much stronger than 
those in the Swab A samples in every case. Leftover ethanol from the manual 
extraction in Swab A samples could have resulted in ADO and weak allele 
peaks. Ethanol is a well known inhibitor of PCR, and restricted DNA 
amplification would result in ADO. It is also entirely possible that the DNA was 
so degraded in the Swab A samples, that there was little useable DNA for the 
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AB 3500 Genetic Analyzer to analyze, resulting in the weak allele peaks and 
ADO. 
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Figure 11​: Identity Testing STR Allele Peak Results for Swab A and Swab B 
Sample 2985 -  Swab A and Swab B sample 2985 were both run on Applied 
Biosystems 3500 Genetic analyzer for identity testing. Swab A is missing alleles 
peaks in 5 STR loci. In CSF10, Swab A is missing an allele peak at 12 repeats. 
In D13S317, Swab A is missing an allele peak at 9 repeats. In D21S11, Swab A 
is missing an allele peak at 29 repeats. In D2S1338, Swab A is missing an allele 
peak at 18 repeats. In THO1, Swab A is missing an allele peak at 9 repeats. 
Based off the fact that all the allele peaks in the Swab A sample were very 
weak, the missing allele peaks were most likely due to allele dropout caused by 
either leftover ethanol from the manual DNA extraction or DNA degradation. The 
residual ethanol would inhibit PCR amplification, resulting in low allele peaks 
and missing polymorphisms. In addition, if the sample DNA was degraded to the 
point that it was unrecognizable to the instrument that would also cause weak 
allele peaks and ADO.  
 
       ​III. Buccal Swab Specimen Failure  
While no concrete cause for the unreportable buccal swab specimen 
copy number results was discovered, there are several possible reasons for the 
discrepancies. Swab A sample DNA was extracted using the ​Gentra Puregene 
Buccal Cell kit and Gentra Puregene Handbook Protocol for DNA Purification 
from a Buccal brush, a manual extraction. The protocol called for the DNA pellet 
to be air-dried for 5 minutes after removing the ethanol. For some samples, this 
might not have been enough time for all the ethanol to evaporate, and therefore 
residual ethanol could have impeded downstream PCR. In theory, however, this 
should have not caused the erroneous calculated copy number results. PCR 
inhibition should be fairly uniform across the genome and since the copy 
number results at calculated by a ratio of the reference concentration : target 
concentration the end result should be the same. The only thing that would be 
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affected would be the concentration of target/reference per mcL, not the 
calculated copy number. 
Poor reagent quality is another possible factor behind  the erroneous 
copy number results. It has been previously documented in-lab that patient 
blood samples isolated manually using the same reagents and a similar protocol 
have had problems in downstream testing. This was not a common issue in this 
study’s blood samples, but could be connected the erroneous copy numbers 
seen in the Swab A samples.  
However, the most likely reason for why a portion of Swab A and Swab B 
samples had unreportable copy number results is non-uniform sample 
degradation.  All buccal swab specimens, regardless of DNA extraction protocol 
or calculated copy number result exhibited DNA degradation when run on a gel 
(Figure 9 and 10). The instability of buccal swab DNA is drawback to the 
specimen type and is in stark contrast to the blood samples (Figure 9). It is quite 
possible that in some samples the DNA was so degraded in some of the 
samples that correct, reliable copy number was impossible. It is also entirely 
possible that the DNA degradation was non-uniform across the genome. 
Degradation could occur anywhere throughout the genome and if areas 
including ​SMN1​ and ​SMN2 ​were degraded more or less than areas including 
RPP30 ​that would cause an imbalance between concentrations of reference and 
target genes. The end result would be a calculated copy number that falls 
outside of a reportable region.  
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       ​ IV.     Limitations and Further Investigations 
There were several limitations in this study that could be addressed by 
further investigation. There was no assessment of what the best storage 
conditions were for the buccal swabs. The Swab A extraction protocol indicated 
that the samples could be stored up to 1 month at room temperature but further 
tests could be done to investigate at what point the length of storage time 
impacts copy number results, if it does at all. There was also very little literature 
about the best way to store Swab B samples, so they were stored at room 
temperature as well. The swabs did come with storage media, but it was 
discarded due to being expired. The use of the storage media might have 
resulted in extracted DNA that was more stable and yielded calculated copy 
number results closer to the reportable result. Further testing could be done to 
re-evaluate the swabs using the storage media.  
There were also no samples used in the study that were SMA positive. 
The group of volunteers was made up of health appearing adults and there were 
no opportunities to get a buccal swab from a SMA patient. There were copy 
number controls used instead to supplement the lack of SMA positive samples, 
but the limitation is important to note.  
While the two types of buccal swabs used in this study proved to not be 
suitable for clinically screening and diagnosing SMA on Bio-Rads ddPCR assay, 
that does not mean there are not other non-invasive specimens available. There 
might be another buccal swab and extraction protocol that would fare better. 
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There are also a number of other non-invasive options for acquiring DNA from 
pediatric patients. The Newborn Screening Panel screens newborn babies for a 
multitude of genetic disorders with a few drops of blood from a heel prick. 
Further studies could be done using the same filter paper as the NBS panel to 
screen and diagnose for SMA.  
The fact that only a portion of the buccal swab specimens did yield 
accurate and  reportable copy number results suggests that it is possible to 
diagnose and screen SMA using non-invasive methods of sample collection. 
The clinical utility behind having a validated non-invasive method of diagnosing 
SMA warrants further investigation to rectify the issues seen in the buccal swab 
specimens of this study.  
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Appendix 
Sampl
e 
Name 
Draw 
Date  
Isolation 
Date  
DNA 
Quant 
(ng/mcL) 
280/2
30 
260/23
0 
Blood 
Result
s 
SMN1  
Blood 
Result
s 
SMN2  
Averag
e 
SMN1 
Average 
SMN2 
Within QC 
range?  
Do the 
Blood and 
Cytosoft 
Brush 
results 
correlate?  
1347  2.4.19 2.9.19 73.6 1.65 0.58 2 2 1.8533
33333 
1.866666
667 
yes Yes  
 
8273  2.4.19 2.9.19 37.4 1.85 0.5 2 2 1.93 1.93 yes Yes 
 
6011 2.4.19 2.9.19 41.2 1.77 0.38 2 2 1.8966
66667 
1.95 yes Yes 
 
5997 2.4.19 2.9.19 80.6 1.75 0.76 2 2 1.8666
66667 
1.933333
333 
yes yes 
2431 2.4.19 2.9.19 42.1 1.77 0.48 2 2 2.0033
33333 
2.113333
333 
yes yes 
2731 2.4.19 2.9.19 34.2 1.91 0.32 2 1 1.9366
6 
0.963333
33 
yes yes 
9137 2.7.19 2.13.19 11 1.94 0.29 2 1 2.15 1.02 yes yes 
7248 2.11.1
9 
2.13.19 131.4 1.79 1.25 2 1 2.1633
33333 
1.133333
333 
no yes 
3594 2.11.1
9 
2.13.19 88.1 1.61 0.62 2 1 2.39 1.37 no yes 
4297 2.11.1
9 
2.13.19 79.6 1.75 0.73 2 2 2.3725 2.4175 no yes 
5263 2.11.1
9 
2.13.19 183.1 1.72 1.08 2 3 2.0633
33333 
3.053333
333 
yes yes 
4990 2.12.1
9 
2.13.19 51 1.82 0.76 2 2 1.9533
33333 
1.946666
667 
yes yes 
2030 2.12.1
9 
2.13.19 20.9 1.78 0.44 2 1 2.435 1.2 no yes 
1286 2.15.1
9 
2.22.19 78.8 1.71 0.75 2 2 1.935 2.035 yes yes 
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1322 2.15.1
9 
2.22.19 57.5 1.72 0.71 2 0 2.005 0 yes yes 
4167 2.21.1
9 
2.22.19 145.8 1.82 1.22 3 0 3.6433
33333 
6.66667E
-05 
yes no 
6077 2.21.1
9 
2.22.19 262.1 1.71 0.99 1 0 1.21 0.019 no yes 
3636 3.6.19 3.11.19 119.2 1.81 1.36 2 1 2.52 1.33 no no 
7041 3.6.19 3.11.19 36 1.6 0.91 2 2 2.36 2.35 no yes 
1625 3.6.19 3.11.19 31 1.6 0.68 2 2 2.27 2.43 no  yes  
Appendix 1:​ Average Copy Number Results for Cytosoft Cytology Brush 
Samples Group 1- Above find the dates for when each of 20 Cytosoft Cytology 
Brush Samples were obtained and isolated  from the volunteers including the 
subsequent extracted concentrations in ng/mcL, 260/280 ratio and 260/230 
ratios. The chart also displays the average SMN1 and SMN2 copy number 
results calculated from all the run results seen in Chart #1. The sample numbers 
in red designate the Cytosoft samples that did not fall within the 10% region of 
acceptable deviation for the possible whole copy number result. The 
corresponding blood sample results were included and the Cytosoft Cytology 
brush samples that did not yield results that correlated to the blood results either 
by falling within the QC region or via rounding are highlighted in yellow. 
 
 
 
Cytosoft 
Cytology 
Brush 
Sample 
number  
SMN1  SMN2 Within 
Range 
results?  
Copan Swab 
Sample 
Number 
SMN1  SMN2 Within Range 
results? 
Do Cytosoft 
and Copan 
sample yield 
the same 
result? 
 
5741 2.18 3.41 no 5741 1.91 2.83 yes Yes  
1277 2.3 2.3 no 1277 1.83 1.85 yes Yes 
3489 2.47 0 no 3489 1.95 0 yes Yes  
4259 2.3 2.31 no 4259 1.93 1.8 yes yes 
1723 2 2 yes 1723 1.75 1.68 no yes 
2985 1.77 0.82 no 2985 1.88 0.906 yes yes 
9111 1.19 0 no 9111 0.918 0 yes yes 
3177 2.05 2.08 yes 3177 2.02 2.08 yes yes 
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9876 1.95 1 yes 9876 1.96 0.91 yes yes 
4922 3.81 0 yes 4922 2.87 0.0006 yes no 
7177 2.29 1.14 no 7177 1.85 0.96 yes yes 
4466 2.17 1.09 yes 4466 1.93 0.94 yes yes 
8556 2.26 1.15 no 8556 1.88 1.01 yes yes 
9378 2.38 2.41 no 9378 1.88 1.87 yes Yes 
6184 2.39 2.35 no 6184 1.94 1.89 yes yes 
7119 2.2 2.28 no 7119 1.92 1.98 yes yes 
1989 2.63 2.62 no 1989 1.94 1.89 yes no 
6860 2.53 1.32 no 6860 1.87 0.965 yes no 
2238 2.6 2.91 no 2238 1.97 1.97 yes no 
2000 2.02 2.02 yes 2000 1.8 1.8 yes Yes 
Appendix 2: ​Group 2 Cytosoft Cytology Brush Specimens versus ​Copan 
4N6FLOQSwab samples - The same 20 volunteers that donated blood and 
cheek swabs in the beginning of the experiment were re-swabbed with Copan 
4N6FLOQSwabx and ​Cytosoft Cytology Brushes. The copy number results of 
each pair of swabs ​can be found above. Samples that fell outside the 10% 
region of acceptable deviation are in red. ​Cytosoft Cytology brush and Copan 
swab samples that had results that did not indicate a genotype from the original 
group of blood sample by either falling within a reportable region or via rounding 
are highlighted in yellow.  
 
 
 
 
 
 
Sample 
Name 
Blood 
Results 
SMN1  
Blood 
Results 
SMN2  
SMN1 SMN2 SMN1 SMN2 SMN1 SMN2 SMN1 SMN2 
1347  2 2 1.82 1.82 1.83 1.9 1.91 1.88     
8273 2 2 1.95 1.96 1.92 1.94 1.92 1.89     
6011 2 2 1.9 1.92 1.82 1.99 1.97 1.94     
5997 2 2 1.83 1.87 1.89 1.97 1.88 1.96     
2431 2 2 2.06 2.09 1.91 2.09 2.04 2.16     
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2731 2 1 1.93 0.94 1.95 0.94 1.93 1.01     
9137 2 1 2.15 1.02             
7248 2 1 2.25 1.14 2.07 1.21 2.17 1.05     
3594 2 1 2.49 1.68 2.33 1.3 2.33 1.3 2.41 1.2 
4297 2 2 2.41 2.3 2.36 2.63 2.49 2.38 2.23 2.36 
5263 2 3 2.09 3.08 2.04 3.09 2.06 2.99     
4990 2 2 2.04 1.95 1.9 2.05 1.92 1.84     
2030 2 1 2.42 1.24 2.45 1.16         
1286 2 2 1.88 1.97 1.99 2.1         
1322 2 0 2.03 0 1.98 0         
4167 3 0 3.65 0.0002 3.74 0 3.54 0     
6077 1 0 1.22 0 1.2 0.057 1.21 0     
3636 2 1 2.52 1.33             
7041 2 2 2.36 2.35             
1625 2 2 2.27 2.43             
Appendix 3.​ Copy Number Results for Cytosoft Cytology Brush Samples Group 
1 Per Run - 20 blood and buccal swab samples were run on Bio-Rad’s SMA 
ddPCR assay and above are the copy number results for every time the sample 
was run. Only the whole number value for the blood samples’ copy number 
results due to their previous validation. Copy number results in red are those 
that fell outside the 10% range of acceptable deviation. Samples that had copy 
number results that fell outside the 10% range of acceptable deviation, this 
includes samples 7248, 3594, 4297, 2030, 4167, 6077, 3636, 7041, and 1625.  
 
 
Sample Original 
Concentration 
(ng/mcL) 
Concentration 
Redo 1 
(ng/mcL) 
Concentration 
Redo 2 (ng/mcL) 
Average 
Concentration 
(ng/mcL) 
Percent 
Change  
4167 blood  73.4 73.8 73.3 73.55 0.204359673 
4167 swab  145.8 90.3 89.2 89.75 38.4430727 
6077 blood  87.1 89.4 90.5 89.95 3.272101033 
6077 swab  262.1 148.5 151.8 150.15 42.71270507 
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7248 blood  84 82.6 83 82.8 1.428571429 
7248 swab  131.4 88.7 88.5 88.6 32.57229833 
3594 blood  76 68.3 73.2 70.75 6.907894737 
3594 swab  88.1 63.2 63.4 63.3 28.14982974 
4297 blood  62.6 63.7 63.1 63.4 1.277955272 
4297 swab  79.6 50 52.3 51.15 35.74120603 
5263 blood  59.1 58.8 64.2 61.5 4.060913706 
5263 swab  183.1 115.4 115.2 115.3 37.02894593 
4990 blood  76.8 72.9 72.7 72.8 5.208333333 
4990 swab  51 34.6 32.8 33.7 33.92156863 
2030 blood  93.4 91 91.1 91.05 2.516059957 
2030 swab 20.9 20.7 21.1 20.9 0 
1286 swab  78.8 38.8 39.5 39.15 50.31725888 
1322 swab  57.5 39 36.6 37.8 34.26086957 
Appendix 4​: DNA Degradation in Buccal Swab Specimens - 10 Swab A 
samples and 8 blood samples were Nanodropped a second and third time to 
see if DNA had degraded over time. All but one of the buccal swab samples had 
a significant decrease in concentration (> 10% change) while none of the blood 
samples did. The average decrease in DNA concentration for the buccal swab 
samples was 33%. The average decrease in DNA concentration for the blood 
samples was 3%. The drastic decrease in DNA concentration in the buccal 
swab samples suggest DNA degradation over time 
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